In patients with acute myocardial infarction, pretreatment with monteplase, a new thrombolytic agent that does not influence plasminogen activator inhibitor-1 (PAI-1) activity, before coronary angioplasty is a promising treatment strategy.
These are the initial results of the COMA (COmbining Monteplase with Angioplasty) Trial, reported by a Japanese team in the October issue of the American Heart Journal.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!